ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long-Acting Schizophrenia Drug Market Research Report 2024
Published Date: April 2024
|
Report Code: QYRE-Auto-31T11783
Home | Market Reports | Health| Mental Health
Global Long Acting Schizophrenia Drug Market Research Report 2022
BUY CHAPTERS

Global Long-Acting Schizophrenia Drug Market Research Report 2024

Code: QYRE-Auto-31T11783
Report
April 2024
Pages:102
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Johnson & Johnson
TEVA
Eli Lilly
Bristol–Myers Squibb
Astrazeneca plc
Sumitomo Dainippon Pharma
Allergan plc
Novartis
Cardinal Health
Sun Pharmaceutical Industries
GlaxoSmithKline PLC
Sanis Health
Qilu Pharmaceutical
Otsuka Pharmaceutical
Vanda Pharmaceuticals
H.Lundbeck
Organon
HANSOH
Hengrui
Nhwa-group
Yangtze River Pharmaceutical Group

Long-Acting Schizophrenia Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Long-Acting Schizophrenia Drug Market

Long-Acting Schizophrenia Drug Market

Second-generation antipsychotics are serotonin-dopamine antagonists and are also known as atypical antipsychotics.
The global Long-Acting Schizophrenia Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Schizophrenia Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Schizophrenia Drug.

Report Scope

The Long-Acting Schizophrenia Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Long-Acting Schizophrenia Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting Schizophrenia Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Long-Acting Schizophrenia Drug Market Report

Report Metric Details
Report Name Long-Acting Schizophrenia Drug Market
CAGR 5%
Segment by Type
  • Oral
  • Injection
Segment by Application
  • Hospital
  • Pharmacies
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Sumitomo Dainippon Pharma, Allergan, Novartis, Cardinal Health, Sun Pharmaceutical Industries, GlaxoSmithKline, Sanis Health, Qilu Pharmaceutical, Otsuka Pharmaceutical, Vanda Pharmaceuticals, H.Lundbeck, Organon, Hansoh, Hengrui, Nhwa Group, Yangtze River Pharmaceutical Group
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Long-Acting Schizophrenia Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Long-Acting Schizophrenia Drug Market report?

Ans: The main players in the Long-Acting Schizophrenia Drug Market are Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Sumitomo Dainippon Pharma, Allergan, Novartis, Cardinal Health, Sun Pharmaceutical Industries, GlaxoSmithKline, Sanis Health, Qilu Pharmaceutical, Otsuka Pharmaceutical, Vanda Pharmaceuticals, H.Lundbeck, Organon, Hansoh, Hengrui, Nhwa Group, Yangtze River Pharmaceutical Group

What are the Application segmentation covered in the Long-Acting Schizophrenia Drug Market report?

Ans: The Applications covered in the Long-Acting Schizophrenia Drug Market report are Hospital, Pharmacies, Other

What are the Type segmentation covered in the Long-Acting Schizophrenia Drug Market report?

Ans: The Types covered in the Long-Acting Schizophrenia Drug Market report are Oral, Injection

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Schizophrenia Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Long-Acting Schizophrenia Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacies
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Schizophrenia Drug Market Perspective (2019-2030)
2.2 Long-Acting Schizophrenia Drug Growth Trends by Region
2.2.1 Global Long-Acting Schizophrenia Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Long-Acting Schizophrenia Drug Historic Market Size by Region (2019-2024)
2.2.3 Long-Acting Schizophrenia Drug Forecasted Market Size by Region (2025-2030)
2.3 Long-Acting Schizophrenia Drug Market Dynamics
2.3.1 Long-Acting Schizophrenia Drug Industry Trends
2.3.2 Long-Acting Schizophrenia Drug Market Drivers
2.3.3 Long-Acting Schizophrenia Drug Market Challenges
2.3.4 Long-Acting Schizophrenia Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Schizophrenia Drug Players by Revenue
3.1.1 Global Top Long-Acting Schizophrenia Drug Players by Revenue (2019-2024)
3.1.2 Global Long-Acting Schizophrenia Drug Revenue Market Share by Players (2019-2024)
3.2 Global Long-Acting Schizophrenia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Long-Acting Schizophrenia Drug Revenue
3.4 Global Long-Acting Schizophrenia Drug Market Concentration Ratio
3.4.1 Global Long-Acting Schizophrenia Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Schizophrenia Drug Revenue in 2023
3.5 Long-Acting Schizophrenia Drug Key Players Head office and Area Served
3.6 Key Players Long-Acting Schizophrenia Drug Product Solution and Service
3.7 Date of Enter into Long-Acting Schizophrenia Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Schizophrenia Drug Breakdown Data by Type
4.1 Global Long-Acting Schizophrenia Drug Historic Market Size by Type (2019-2024)
4.2 Global Long-Acting Schizophrenia Drug Forecasted Market Size by Type (2025-2030)
5 Long-Acting Schizophrenia Drug Breakdown Data by Application
5.1 Global Long-Acting Schizophrenia Drug Historic Market Size by Application (2019-2024)
5.2 Global Long-Acting Schizophrenia Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Long-Acting Schizophrenia Drug Market Size (2019-2030)
6.2 North America Long-Acting Schizophrenia Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Long-Acting Schizophrenia Drug Market Size by Country (2019-2024)
6.4 North America Long-Acting Schizophrenia Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Schizophrenia Drug Market Size (2019-2030)
7.2 Europe Long-Acting Schizophrenia Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Long-Acting Schizophrenia Drug Market Size by Country (2019-2024)
7.4 Europe Long-Acting Schizophrenia Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Schizophrenia Drug Market Size (2019-2030)
8.2 Asia-Pacific Long-Acting Schizophrenia Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Schizophrenia Drug Market Size (2019-2030)
9.2 Latin America Long-Acting Schizophrenia Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Long-Acting Schizophrenia Drug Market Size by Country (2019-2024)
9.4 Latin America Long-Acting Schizophrenia Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Schizophrenia Drug Market Size (2019-2030)
10.2 Middle East & Africa Long-Acting Schizophrenia Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Long-Acting Schizophrenia Drug Introduction
11.1.4 Johnson & Johnson Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.1.5 Johnson & Johnson Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Long-Acting Schizophrenia Drug Introduction
11.2.4 Teva Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Long-Acting Schizophrenia Drug Introduction
11.3.4 Eli Lilly Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.3.5 Eli Lilly Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Detail
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Long-Acting Schizophrenia Drug Introduction
11.4.4 Bristol Myers Squibb Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.4.5 Bristol Myers Squibb Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Long-Acting Schizophrenia Drug Introduction
11.5.4 AstraZeneca Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.5.5 AstraZeneca Recent Development
11.6 Sumitomo Dainippon Pharma
11.6.1 Sumitomo Dainippon Pharma Company Detail
11.6.2 Sumitomo Dainippon Pharma Business Overview
11.6.3 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Introduction
11.6.4 Sumitomo Dainippon Pharma Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.6.5 Sumitomo Dainippon Pharma Recent Development
11.7 Allergan
11.7.1 Allergan Company Detail
11.7.2 Allergan Business Overview
11.7.3 Allergan Long-Acting Schizophrenia Drug Introduction
11.7.4 Allergan Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.7.5 Allergan Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Long-Acting Schizophrenia Drug Introduction
11.8.4 Novartis Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 Cardinal Health
11.9.1 Cardinal Health Company Detail
11.9.2 Cardinal Health Business Overview
11.9.3 Cardinal Health Long-Acting Schizophrenia Drug Introduction
11.9.4 Cardinal Health Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.9.5 Cardinal Health Recent Development
11.10 Sun Pharmaceutical Industries
11.10.1 Sun Pharmaceutical Industries Company Detail
11.10.2 Sun Pharmaceutical Industries Business Overview
11.10.3 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Introduction
11.10.4 Sun Pharmaceutical Industries Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.10.5 Sun Pharmaceutical Industries Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Detail
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Long-Acting Schizophrenia Drug Introduction
11.11.4 GlaxoSmithKline Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.11.5 GlaxoSmithKline Recent Development
11.12 Sanis Health
11.12.1 Sanis Health Company Detail
11.12.2 Sanis Health Business Overview
11.12.3 Sanis Health Long-Acting Schizophrenia Drug Introduction
11.12.4 Sanis Health Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.12.5 Sanis Health Recent Development
11.13 Qilu Pharmaceutical
11.13.1 Qilu Pharmaceutical Company Detail
11.13.2 Qilu Pharmaceutical Business Overview
11.13.3 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Introduction
11.13.4 Qilu Pharmaceutical Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.13.5 Qilu Pharmaceutical Recent Development
11.14 Otsuka Pharmaceutical
11.14.1 Otsuka Pharmaceutical Company Detail
11.14.2 Otsuka Pharmaceutical Business Overview
11.14.3 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Introduction
11.14.4 Otsuka Pharmaceutical Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.14.5 Otsuka Pharmaceutical Recent Development
11.15 Vanda Pharmaceuticals
11.15.1 Vanda Pharmaceuticals Company Detail
11.15.2 Vanda Pharmaceuticals Business Overview
11.15.3 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Introduction
11.15.4 Vanda Pharmaceuticals Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.15.5 Vanda Pharmaceuticals Recent Development
11.16 H.Lundbeck
11.16.1 H.Lundbeck Company Detail
11.16.2 H.Lundbeck Business Overview
11.16.3 H.Lundbeck Long-Acting Schizophrenia Drug Introduction
11.16.4 H.Lundbeck Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.16.5 H.Lundbeck Recent Development
11.17 Organon
11.17.1 Organon Company Detail
11.17.2 Organon Business Overview
11.17.3 Organon Long-Acting Schizophrenia Drug Introduction
11.17.4 Organon Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.17.5 Organon Recent Development
11.18 Hansoh
11.18.1 Hansoh Company Detail
11.18.2 Hansoh Business Overview
11.18.3 Hansoh Long-Acting Schizophrenia Drug Introduction
11.18.4 Hansoh Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.18.5 Hansoh Recent Development
11.19 Hengrui
11.19.1 Hengrui Company Detail
11.19.2 Hengrui Business Overview
11.19.3 Hengrui Long-Acting Schizophrenia Drug Introduction
11.19.4 Hengrui Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.19.5 Hengrui Recent Development
11.20 Nhwa Group
11.20.1 Nhwa Group Company Detail
11.20.2 Nhwa Group Business Overview
11.20.3 Nhwa Group Long-Acting Schizophrenia Drug Introduction
11.20.4 Nhwa Group Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.20.5 Nhwa Group Recent Development
11.21 Yangtze River Pharmaceutical Group
11.21.1 Yangtze River Pharmaceutical Group Company Detail
11.21.2 Yangtze River Pharmaceutical Group Business Overview
11.21.3 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Introduction
11.21.4 Yangtze River Pharmaceutical Group Revenue in Long-Acting Schizophrenia Drug Business (2019-2024)
11.21.5 Yangtze River Pharmaceutical Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Johnson & Johnson
TEVA
Eli Lilly
Bristol–Myers Squibb
Astrazeneca plc
Sumitomo Dainippon Pharma
Allergan plc
Novartis
Cardinal Health
Sun Pharmaceutical Industries
GlaxoSmithKline PLC
Sanis Health
Qilu Pharmaceutical
Otsuka Pharmaceutical
Vanda Pharmaceuticals
H.Lundbeck
Organon
HANSOH
Hengrui
Nhwa-group
Yangtze River Pharmaceutical Group
List of Tables
    Table 1. Global Long-Acting Schizophrenia Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Oral
    Table 3. Key Players of Injection
    Table 4. Global Long-Acting Schizophrenia Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 5. Global Long-Acting Schizophrenia Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Long-Acting Schizophrenia Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global Long-Acting Schizophrenia Drug Market Share by Region (2019-2024)
    Table 8. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global Long-Acting Schizophrenia Drug Market Share by Region (2025-2030)
    Table 10. Long-Acting Schizophrenia Drug Market Trends
    Table 11. Long-Acting Schizophrenia Drug Market Drivers
    Table 12. Long-Acting Schizophrenia Drug Market Challenges
    Table 13. Long-Acting Schizophrenia Drug Market Restraints
    Table 14. Global Long-Acting Schizophrenia Drug Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global Long-Acting Schizophrenia Drug Market Share by Players (2019-2024)
    Table 16. Global Top Long-Acting Schizophrenia Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Schizophrenia Drug as of 2023)
    Table 17. Ranking of Global Top Long-Acting Schizophrenia Drug Companies by Revenue (US$ Million) in 2023
    Table 18. Global 5 Largest Players Market Share by Long-Acting Schizophrenia Drug Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Long-Acting Schizophrenia Drug Product Solution and Service
    Table 21. Date of Enter into Long-Acting Schizophrenia Drug Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Long-Acting Schizophrenia Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global Long-Acting Schizophrenia Drug Revenue Market Share by Type (2019-2024)
    Table 25. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global Long-Acting Schizophrenia Drug Revenue Market Share by Type (2025-2030)
    Table 27. Global Long-Acting Schizophrenia Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global Long-Acting Schizophrenia Drug Revenue Market Share by Application (2019-2024)
    Table 29. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global Long-Acting Schizophrenia Drug Revenue Market Share by Application (2025-2030)
    Table 31. North America Long-Acting Schizophrenia Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 32. North America Long-Acting Schizophrenia Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 33. North America Long-Acting Schizophrenia Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 34. Europe Long-Acting Schizophrenia Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 35. Europe Long-Acting Schizophrenia Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 36. Europe Long-Acting Schizophrenia Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 37. Asia-Pacific Long-Acting Schizophrenia Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 38. Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 39. Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Long-Acting Schizophrenia Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 41. Latin America Long-Acting Schizophrenia Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 42. Latin America Long-Acting Schizophrenia Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 43. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Johnson & Johnson Company Detail
    Table 47. Johnson & Johnson Business Overview
    Table 48. Johnson & Johnson Long-Acting Schizophrenia Drug Product
    Table 49. Johnson & Johnson Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 50. Johnson & Johnson Recent Development
    Table 51. Teva Company Detail
    Table 52. Teva Business Overview
    Table 53. Teva Long-Acting Schizophrenia Drug Product
    Table 54. Teva Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 55. Teva Recent Development
    Table 56. Eli Lilly Company Detail
    Table 57. Eli Lilly Business Overview
    Table 58. Eli Lilly Long-Acting Schizophrenia Drug Product
    Table 59. Eli Lilly Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 60. Eli Lilly Recent Development
    Table 61. Bristol Myers Squibb Company Detail
    Table 62. Bristol Myers Squibb Business Overview
    Table 63. Bristol Myers Squibb Long-Acting Schizophrenia Drug Product
    Table 64. Bristol Myers Squibb Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 65. Bristol Myers Squibb Recent Development
    Table 66. AstraZeneca Company Detail
    Table 67. AstraZeneca Business Overview
    Table 68. AstraZeneca Long-Acting Schizophrenia Drug Product
    Table 69. AstraZeneca Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 70. AstraZeneca Recent Development
    Table 71. Sumitomo Dainippon Pharma Company Detail
    Table 72. Sumitomo Dainippon Pharma Business Overview
    Table 73. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product
    Table 74. Sumitomo Dainippon Pharma Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 75. Sumitomo Dainippon Pharma Recent Development
    Table 76. Allergan Company Detail
    Table 77. Allergan Business Overview
    Table 78. Allergan Long-Acting Schizophrenia Drug Product
    Table 79. Allergan Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 80. Allergan Recent Development
    Table 81. Novartis Company Detail
    Table 82. Novartis Business Overview
    Table 83. Novartis Long-Acting Schizophrenia Drug Product
    Table 84. Novartis Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 85. Novartis Recent Development
    Table 86. Cardinal Health Company Detail
    Table 87. Cardinal Health Business Overview
    Table 88. Cardinal Health Long-Acting Schizophrenia Drug Product
    Table 89. Cardinal Health Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 90. Cardinal Health Recent Development
    Table 91. Sun Pharmaceutical Industries Company Detail
    Table 92. Sun Pharmaceutical Industries Business Overview
    Table 93. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product
    Table 94. Sun Pharmaceutical Industries Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 95. Sun Pharmaceutical Industries Recent Development
    Table 96. GlaxoSmithKline Company Detail
    Table 97. GlaxoSmithKline Business Overview
    Table 98. GlaxoSmithKline Long-Acting Schizophrenia Drug Product
    Table 99. GlaxoSmithKline Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 100. GlaxoSmithKline Recent Development
    Table 101. Sanis Health Company Detail
    Table 102. Sanis Health Business Overview
    Table 103. Sanis Health Long-Acting Schizophrenia Drug Product
    Table 104. Sanis Health Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 105. Sanis Health Recent Development
    Table 106. Qilu Pharmaceutical Company Detail
    Table 107. Qilu Pharmaceutical Business Overview
    Table 108. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product
    Table 109. Qilu Pharmaceutical Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 110. Qilu Pharmaceutical Recent Development
    Table 111. Otsuka Pharmaceutical Company Detail
    Table 112. Otsuka Pharmaceutical Business Overview
    Table 113. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product
    Table 114. Otsuka Pharmaceutical Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 115. Otsuka Pharmaceutical Recent Development
    Table 116. Vanda Pharmaceuticals Company Detail
    Table 117. Vanda Pharmaceuticals Business Overview
    Table 118. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product
    Table 119. Vanda Pharmaceuticals Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 120. Vanda Pharmaceuticals Recent Development
    Table 121. H.Lundbeck Company Detail
    Table 122. H.Lundbeck Business Overview
    Table 123. H.Lundbeck Long-Acting Schizophrenia Drug Product
    Table 124. H.Lundbeck Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 125. H.Lundbeck Recent Development
    Table 126. Organon Company Detail
    Table 127. Organon Business Overview
    Table 128. Organon Long-Acting Schizophrenia Drug Product
    Table 129. Organon Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 130. Organon Recent Development
    Table 131. Hansoh Company Detail
    Table 132. Hansoh Business Overview
    Table 133. Hansoh Long-Acting Schizophrenia Drug Product
    Table 134. Hansoh Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 135. Hansoh Recent Development
    Table 136. Hengrui Company Detail
    Table 137. Hengrui Business Overview
    Table 138. Hengrui Long-Acting Schizophrenia Drug Product
    Table 139. Hengrui Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 140. Hengrui Recent Development
    Table 141. Nhwa Group Company Detail
    Table 142. Nhwa Group Business Overview
    Table 143. Nhwa Group Long-Acting Schizophrenia Drug Product
    Table 144. Nhwa Group Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 145. Nhwa Group Recent Development
    Table 146. Yangtze River Pharmaceutical Group Company Detail
    Table 147. Yangtze River Pharmaceutical Group Business Overview
    Table 148. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product
    Table 149. Yangtze River Pharmaceutical Group Revenue in Long-Acting Schizophrenia Drug Business (2019-2024) & (US$ Million)
    Table 150. Yangtze River Pharmaceutical Group Recent Development
    Table 151. Research Programs/Design for This Report
    Table 152. Key Data Information from Secondary Sources
    Table 153. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Long-Acting Schizophrenia Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Long-Acting Schizophrenia Drug Market Share by Type: 2023 VS 2030
    Figure 3. Oral Features
    Figure 4. Injection Features
    Figure 5. Global Long-Acting Schizophrenia Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 6. Global Long-Acting Schizophrenia Drug Market Share by Application: 2023 VS 2030
    Figure 7. Hospital Case Studies
    Figure 8. Pharmacies Case Studies
    Figure 9. Other Case Studies
    Figure 10. Long-Acting Schizophrenia Drug Report Years Considered
    Figure 11. Global Long-Acting Schizophrenia Drug Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Long-Acting Schizophrenia Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Long-Acting Schizophrenia Drug Market Share by Region: 2023 VS 2030
    Figure 14. Global Long-Acting Schizophrenia Drug Market Share by Players in 2023
    Figure 15. Global Top Long-Acting Schizophrenia Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Schizophrenia Drug as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Long-Acting Schizophrenia Drug Revenue in 2023
    Figure 17. North America Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Long-Acting Schizophrenia Drug Market Share by Country (2019-2030)
    Figure 19. United States Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. Canada Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Europe Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Europe Long-Acting Schizophrenia Drug Market Share by Country (2019-2030)
    Figure 23. Germany Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. France Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. U.K. Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Italy Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Russia Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Nordic Countries Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Asia-Pacific Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Asia-Pacific Long-Acting Schizophrenia Drug Market Share by Region (2019-2030)
    Figure 31. China Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Japan Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. South Korea Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Southeast Asia Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. India Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Australia Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Latin America Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Latin America Long-Acting Schizophrenia Drug Market Share by Country (2019-2030)
    Figure 39. Mexico Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Brazil Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Middle East & Africa Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa Long-Acting Schizophrenia Drug Market Share by Country (2019-2030)
    Figure 43. Turkey Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Saudi Arabia Long-Acting Schizophrenia Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Johnson & Johnson Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 46. Teva Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 47. Eli Lilly Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 48. Bristol Myers Squibb Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 49. AstraZeneca Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 50. Sumitomo Dainippon Pharma Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 51. Allergan Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 52. Novartis Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 53. Cardinal Health Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 54. Sun Pharmaceutical Industries Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 55. GlaxoSmithKline Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 56. Sanis Health Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 57. Qilu Pharmaceutical Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 58. Otsuka Pharmaceutical Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 59. Vanda Pharmaceuticals Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 60. H.Lundbeck Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 61. Organon Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 62. Hansoh Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 63. Hengrui Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 64. Nhwa Group Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 65. Yangtze River Pharmaceutical Group Revenue Growth Rate in Long-Acting Schizophrenia Drug Business (2019-2024)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions